GCM
IART icon

Gladius Capital Management’s Integra LifeSciences IART Stock Holding History

Gladius Capital Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,241
Closed -$47.4K – 362
2023
Q3 		$47.4K Buy
+1,241
New +$52.2K ﹤0.01% 215

Other funds holding IART

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gladius Capital Management's IART Position: Q4 2023 in Review

Gladius Capital Management sold out of Integra LifeSciences (IART) in Q4 2023, closing a stake of 1,241 shares — an estimated $47.4K sold.

Gladius Capital Management first reported a position in IART in Q3 2023 and held it in 1 quarter. The position peaked at $47.4K in Q3 2023. 284 funds tracked by Wall St. Rank hold IART as of Q4 2023.

  • Gladius Capital Management reported no remaining Integra LifeSciences position as of Q4 2023 after selling out during the quarter.
  • Gladius Capital Management sold 1,241 Integra LifeSciences shares in Q4 2023, an estimated $47.4K.
  • Gladius Capital Management first reported a position in Integra LifeSciences in Q3 2023 and held it in 1 quarter.
  • Gladius Capital Management's Integra LifeSciences position peaked at $47.4K in Q3 2023.
  • 284 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2023.

Based on Gladius Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.